

# A Prospective Study of Lipoprotein (a) and the Risk of Mortality in Patients with Established Coronary Heart Disease

Stephen Zewinger<sup>1</sup>, Marcus E. Kleber<sup>2,3</sup>, Vinicius Tragante<sup>4</sup>, Raymond O. McCubrey<sup>5</sup>, Amand F Schmidt<sup>6</sup>, Kenan Direk<sup>6</sup>, Ulrich Laufs<sup>7</sup>, Christian Werner<sup>7</sup>, Wolfgang Koenig<sup>8-10</sup>, Dietrich Rothenbacher<sup>11,12</sup>, Ute Mons<sup>11</sup>, Lutz P. Breitling<sup>11</sup>, Herrmann Brenner<sup>11,13</sup>, Richard T. Jennings<sup>1</sup>, Ioannis Petrakis<sup>1</sup>, Sarah Triem<sup>1</sup>, Mira Klug<sup>1</sup>, Alexandra Filips<sup>1</sup>, Stefan Blankenberg<sup>14,15</sup>, Christoph Waldeyer<sup>14,15</sup>, Christoph Sinning<sup>14,15</sup>, Renate B. Schnabel<sup>14,15</sup>, Karl J. Lackner<sup>16</sup>, Efthymia Vlachopoulou<sup>17</sup>, Ottar Nygård<sup>18,19</sup>, Gard Frodahl Tveitevåg Svingen<sup>19</sup>, Eva Ringdal Pedersen<sup>18</sup>, Grethe S. Tell<sup>20</sup>, Juha Sinisalo<sup>21</sup>, Markku S. Nieminen<sup>21</sup>, Reijo Laaksonen<sup>22,23</sup>, Stella Trompet<sup>24,25</sup>, Roelof A. J. Smit<sup>24,25</sup>, Naveed Sattar<sup>26</sup>, J. Wouter Jukema<sup>27,28</sup>, Heinrich V. Groesdonk<sup>29</sup>, Graciela Delgado<sup>2</sup>, Tatjana Stojakovic<sup>30</sup>, Anna P. Pilbrow<sup>31</sup>, Vicky A. Cameron<sup>31</sup>, A. Mark Richards<sup>31,32</sup>, Robert N. Doughty<sup>33</sup>, Yan Gong<sup>34</sup>, Rhonda Cooper-DeHoff<sup>34</sup>, Julie Johnson<sup>34</sup>, Markus Scholz<sup>35,36</sup>, Frank Beutner<sup>37</sup>, Joachim Thiery<sup>36,38</sup>, J. Gustav Smith<sup>39</sup>, Ragnar O. Vilmondarson<sup>40</sup>, Ruth McPherson<sup>40</sup>, Alexandre F. R. Stewart<sup>40</sup>, Sharon Cresci<sup>41</sup>, Petra A. Lenzi<sup>42</sup>, John A. Spertus<sup>43</sup>, Oliviero Olivieri<sup>44</sup>, Domenico Girelli<sup>44</sup>, Nicola Martinelli<sup>44</sup>, Andreas Leihner<sup>45,46</sup>, Christoph H. Saely<sup>45,46</sup>, Heinz Drexler<sup>45-48</sup>, Axel Mündlein<sup>45</sup>, Peter S. Braund<sup>49,50</sup>, Christopher P. Nelson<sup>49,50</sup>, Nilesh J. Samani<sup>49,50</sup>, Daniel Kofink<sup>4</sup>, Imo E. Hofer<sup>51</sup>, Gerard Pasterkamp<sup>51</sup>, Arshed A Quyyumi<sup>52</sup>, Yi-An Ko<sup>52</sup>, Jaana A. Hartiala<sup>53</sup>, Hooman Allayee<sup>53</sup>, W. H. Wilson Tang<sup>54</sup>, Stanley L. Hazen<sup>54</sup>, Niclas Eriksson<sup>55</sup>, Claes Held<sup>55,56</sup>, Emil Hagstrom<sup>55,56</sup>, Lars Wallentin<sup>55,56</sup>, Axel Åkerblom<sup>55,56</sup>, Agneta Siegbahn<sup>57</sup>, Igor Karp<sup>58-60</sup>, Christopher Labos<sup>61</sup>, Louise Pilote<sup>61-63</sup>, James C. Engert<sup>61</sup>, James M. Brophy<sup>61</sup>, George Thanassoulis<sup>61</sup>, Peter Bogaty<sup>64</sup>, Wojciech Szczeklik<sup>65</sup>, Marcin Kaczor<sup>65</sup>, Marek Sanak<sup>65</sup>, Salim S. Virani<sup>66</sup>, Christie M. Ballantyne<sup>67</sup>, Vei-Vei Lee<sup>68</sup>, Eric Boerwinkle<sup>69</sup>, Michael V Holmes<sup>70,71</sup>, Benjamin D. Horne<sup>5</sup>, Aroon Hingorani<sup>6</sup>, Folkert W. Asselbergs<sup>4,72,73</sup>, Riyaz S. Patel<sup>6</sup>, on behalf of the GENIUS-CHD consortium, Bernhard K. Krämer<sup>74</sup>, Hubert Scharnagl<sup>30</sup>, Danilo Fliser<sup>1</sup>, Winfried März<sup>2,30,75\*</sup>, Thimoteus Speer<sup>1\*</sup>

1. Department of Internal Medicine IV, Saarland University Hospital, Homburg/Saar, Germany.
2. Vth Department of Medicine, University Heidelberg, Mannheim Medical Faculty, Mannheim, Germany.
3. Institute of Nutrition, Friedrich-Schiller University, Jena, Germany.

4. Department of Cardiology, Heart & Lungs Division, UMC Utrecht, Utrecht, the Netherlands.
5. Intermountain Heart Institute, Intermountain Medical Center, University of Utah School of Medicine, Salt Lake City, Utah, USA.
6. Institute of Cardiovascular Science, University College London, London, UK.
7. Department of Internal Medicine III, Saarland University Hospital, Homburg/Saar, Germany.
8. Department of Internal Medicine II - Cardiology, University of Ulm Medical Centre, Ulm, Germany.
9. Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
10. German Centre of Cardiovascular Research (DZHK), Partner site Munich Heart Alliance, Munich, Germany.
11. Division of Clinical Epidemiology and Ageing Research, German Cancer Center (DKFZ), Heidelberg, Germany.
12. Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.
13. Network Ageing Research, University of Heidelberg, Germany.
14. University Heart Center Hamburg, Clinic for General and Interventional Cardiology, Hamburg, Germany.
15. German Center for Cardiovascular Research (DZHK e.V.), partner site Hamburg/Kiel/Lübeck, Germany.
16. Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Mainz, Germany.
17. Transplantation Laboratory, Haartman Institute, University of Helsinki, Finland.
18. Department of Clinical Science, University of Bergen, Bergen, Norway.
19. Department of Heart Disease, Haukeland University Hospital, Bergen, Norway.
20. Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
21. Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
22. Medical School, Tampere University, Tampere, Finland.
23. Finnish Clinical Biobank Tampere, University Hospital of Tampere, Tampere, Finland.
24. Department of Geriatrics and Gerontology, Leiden University Medical Center, Leiden, the Netherlands.
25. Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.
26. Institute of Cardiovascular and Medical Science, BHF Glasgow, Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.

27. Department of Cardiology and Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Center, Leiden, the Netherlands.
28. Interuniversity Cardiology Institute of the Netherlands, Utrecht, the Netherlands.
29. Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, Saarland University Hospital, Homburg/Saar, Germany.
30. Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, Graz, Austria.
31. The Christchurch Heart Institute, University of Otago Christchurch, New Zealand.
32. Cardiovascular Research Institute, National University of Singapore, Singapore.
33. Heart Health Research Group, University of Auckland, New Zealand.
34. Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, Colleges of Pharmacy, University of Florida, Gainesville, FL, USA.
35. Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
36. LIFE Research Center for Civilization Diseases, University of Leipzig, Leipzig, Germany.
37. Heart Center Leipzig, Leipzig, Germany.
38. Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital, Leipzig, Germany.
39. Department of Cardiology, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden.
40. Ruddy Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
41. Washington University School of Medicine, Departments of Medicine and Genetics, Saint Louis, Missouri, USA.
42. Washington University School of Medicine, Department of Genetics, Statistical Genomics Division, Saint Louis, Missouri, USA.
43. Saint Luke's Mid America Heart Institute and the University of Missouri-Kansas City, Kansas City, Missouri, USA.
44. Department of Medicine, University of Verona, Verona, Italy.
45. Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.
46. Private University of the Principality of Liechtenstein, Triesen, Liechtenstein.
47. Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.
48. Drexel University College of Medicine, Philadelphia, PA, USA.

49. Department of Cardiovascular Sciences, University of Leicester, BHF Cardiovascular Research Centre, Glenfield Hospital, Leicester, UK.
50. Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, UK.
51. Laboratory of Experimental Cardiology, UMC, Utrecht, the Netherlands.
52. Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, USA.
53. University of Southern California, Los Angeles, CA, USA.
54. Cleveland Clinic, Cleveland, OH, USA.
55. Uppsala Clinical Research Center, Uppsala, Sweden.
56. Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
57. Department of Medical Sciences, Clinical Chemistry and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
58. University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada.
59. Department of Social and Preventive Medicine, University of Montreal, Montreal, Quebec, Canada.
60. Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
61. Department of Medicine, McGill University, Montreal, Quebec, Canada.
62. Division of General Internal Medicine, McGill University Health Centre, Montreal, Quebec, Canada.
63. Division of Clinical Epidemiology, McGill University Health Centre, Montreal, Quebec, Canada.
64. Department of Medicine, Université Laval, Quebec, Canada.
65. Jagiellonian University Medical College, Kraków, Poland.
66. Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center and Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
67. Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
68. Department of Biostatistics 7, Epidemiology, Texas Heart Institute, Houston, TX, USA.
69. University of Texas, School of Public Health, Houston, TX, USA.
70. Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, UK.
71. Medical Research Council Population Health Research Unit at the University of Oxford, UK.

72. Durrer Center of Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, the Netherlands.
73. Institute of Cardiovascular Science, Faculty of Population Health Science, University College London, London, UK.
74. Fifth Department of Medicine, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
75. Synlab Academy, Synlab Holding GmbH, Mannheim, Germany.

\* Both authors contributed equally.

**Corresponding author**

Winfried März, MD

Medical Clinic V

Medical Faculty of Mannheim, University Heidelberg

Theodor-Kutzer-Ufer 1-3

68167 Mannheim, Germany

Phone: +49-621 383-5172

Fax: +49-621 383-3804

Mail: [winfried.maerz@medma.uni-heidelberg.de](mailto:winfried.maerz@medma.uni-heidelberg.de)

## Abstract

### Background:

Epidemiological and genetic studies show an association between lipoprotein(a) (Lp(a)) plasma levels and cardiovascular risk in general population studies. However, in patients with established coronary heart disease (CHD), it remains less clear whether Lp(a) or *LPA* genetic variants predict long-term mortality.

### Methods:

We analyzed the association between Lp(a) plasma concentrations and two *LPA* genetic variants (SNPs, rs10455872, rs3798220) with prevalent CHD phenotypes as well as long-term outcomes in 3,313 participants of the Ludwigshafen Risk and Cardiovascular Health (LURIC) study (median follow-up 9.9 years). Association results for plasma Lp(a) concentrations were validated in five independent studies while genetic association findings were replicated through large scale collaborative analysis within the GENIUS-CHD consortium comprising 24 studies of patients with established CHD.

### Findings:

While, we replicate the association of both plasma levels and SNPs prevalence with severity of CHD (tertile 3 of Lp(a) 1.44, 95% CI 1.14 to 1.83; any *LPA* SNP 1.88, 95 % CI 1.40 to 2.53), Lp(a) levels were not associated with all-cause (tertile 3 of Lp(a) 0.95, 95 % CI 0.81 to 1.11; any *LPA* SNP 1.10, 95% CI 0.92 to 1.31) or cardiovascular mortality (tertile 3 of Lp(a) 0.99, 95 % CI 0.81 to 1.2; any *LPA* SNP 1.13, 95% CI 0.90 to 1.40) during follow-up of patients with established CHD. This finding was confirmed in five independent cohorts of 10,195 CHD patients. Similarly, *LPA* SNPs were not associated with subsequent mortality once CHD had been established, a finding confirmed in a meta-analysis of 106,353 participants with 19,332 events from the GENIUS-CHD consortium (all-cause mortality: *LPA* rs3798220 0.94, 95% CI 0.86 to 1.03; *LPA* rs10455872 0.95, 95% CI 0.90 to 1.03; cardiovascular mortality: *LPA* rs3798220 0.95, 95% CI 0.83 to 1.10; *LPA* rs10455872 0.96, 95% CI 0.88 to 1.05).

### Interpretation:

In patients with prevalent CHD, neither Lp(a) concentrations nor genetic variants associated with Lp(a) concentrations showed any association with subsequent mortality. These data suggest that Lp(a) as risk marker may be more useful in predicting first CHD event onset rather than progression to death after a CHD event.

### Funding:

7th Framework Program (AtheroRemo and RiskyCAD, EU), INTERREG IV Oberrhein Program (A28), Deutsche Nierenstiftung, Else-Kroener Fresenius Foundation, Deutsche Stiftung für Herzforschung, Deutsche Forschungsgemeinschaft, Saarland University,

German Federal Ministry of Education and Research, Willy Robert Pitzer Foundation,  
Waldburg-Zeil Clinics Isny.

## Introduction

Worldwide, cardiovascular disease (CVD) remains the leading cause of death<sup>1</sup>. Lipoprotein (a) (Lp(a)) is regarded as an emerging risk factor and potential therapeutic target, based on independent associations with atherosclerosis and CVD events in general population studies<sup>2,3</sup>. In a meta-analysis dated from the year 2000, the combined risk ratio for coronary heart disease (CHD) was 1.7 (95% confidence interval [CI] 1.4 to 1.9) for the top tertile of Lp(a) compared to the lowest tertile in 18 general population studies<sup>4</sup>. The Copenhagen City Heart Study arrived at a virtually identical risk estimate when comparing the highest to the lowest tertile of Lp(a), while reporting higher risks once Lp(a) exceeded the 90<sup>th</sup> percentile of its frequency distribution<sup>5</sup>. A more recent individual record-based meta-analysis of general population studies excluding participants with a history of CVD at baseline found a continuous, though modest relationship between Lp(a) and the incidence of CHD and stroke, with rates of CHD of 5.6 (95% confidence interval CI 5.4-5.9) and 4.4 (95% CI 4.2-4.6) per 1000 person-years in the highest and in the lowest tertile of Lp(a), respectively<sup>6</sup>.

Lp(a) is composed of a low-density lipoprotein (LDL)-like apolipoprotein B (ApoB)-containing core to which one copy of the apo(a) glycoprotein is attached by a disulfide bridge<sup>7-9</sup>. The physiological function of Lp(a) is not known, nor are the precise mechanisms of synthesis and catabolism. It has been suggested that Lp(a) is assembled on the surface membrane of hepatocytes<sup>10</sup> and a number of cell surface receptors have been implicated in the catabolism of Lp(a)<sup>11</sup>. Lp(a) may have effects on the vascular tree similar to LDL, but has been postulated to be potentially more atherogenic due to specific pro-thrombotic effects<sup>3</sup>. The concentrations of Lp(a) in the circulation vary widely and are related to the number of kringle IV type 2 repeats and further sequence variants of the *LPA* gene<sup>12,13</sup>. Two common *LPA* variants, rs10455872 (intronic non-coding) and rs3798220 (missense variant Ile4399Met in the apo(a) protease-like domain), explain a substantial proportion of the variation of Lp(a) and have consistently been linked to the risk of incident myocardial infarction<sup>14,15</sup>.

Unlike many other traditional risk factors for CHD, Lp(a) is difficult to modify by life-style changes<sup>3</sup>. PCSK9 inhibitors reduce Lp(a) by 20-30 %<sup>16</sup>, but are not yet routinely used for this purpose. Lipoprotein apheresis represents the only currently available approach to substantially lower Lp(a).

The relationship of elevated Lp(a) and future or recurrent cardiac events in patients with established CHD has been studied less extensively and so far appears weaker than in the general population. Further it may be modified by the LDL-cholesterol (LDL-C) concentration<sup>4,17,18</sup>. We therefore sought to examine systematically and at scale the association between Lp(a) and long-term mortality in patients with established CHD.



## Methods

### LURIC study

Between 1997 and 2000, the Ludwigshafen Risk and Cardiovascular Health (LURIC) study enrolled 3,316 German patients undergoing coronary angiography<sup>19</sup>. The study design and examinations at baseline have been described<sup>19</sup>. Written informed consent was obtained from all patients. Participants with acute illnesses other than acute coronary syndromes (ACS), such as malignancy or other chronic non-cardiac diseases within the past five years were excluded. Clinically stable patients (except for ACS) with available coronary angiogram data were enrolled. Information on death during follow-up was obtained from the local Public Health Departments. Cardiovascular mortality was defined as death due to fatal myocardial infarction, sudden cardiac death, death after cardiovascular intervention, stroke and other causes of death caused by cardiovascular diseases.

The study was performed in accordance with the Declaration of Helsinki. An approval by the competent Ethics Committee (Ärzttekammer Rheinland-Palatinat, Germany) was obtained. No patients were lost to follow-up.

### Validation cohorts

Association findings for Lp(a) plasma levels and outcomes were validated in 10,195 participants of the Homburg Cream and Sugar (HCS) study, the KAROLA study, the WENBIT/WECAC study, the PROSPER study and the ATHEROGENE study. For details on these cohorts please see appendix pages 2-3.

### GENIUS-CHD consortium

Genetic association results for SNPs in the *LPA* locus and all-cause, as well as cardiovascular mortality were validated through a collaborative individual participant level analysis through the Genetics of Subsequent Coronary Heart Disease (GENIUS-CHD) consortium ([www.genius-chd.com](http://www.genius-chd.com))<sup>20</sup>. This is a recently formed grouping of multiple international studies of patients with CHD (either stable disease or ACS), who have had blood or tissue samples stored for analysis or have genotyping data and have then been prospectively followed for subsequent events, such as death. Studies with available *LPA* SNP data from the wider GENIUS-CHD consortium were included, and are described in the appendix, page 1.

### Laboratory methods and procedures

In LURIC, blood sampling for measuring Lp(a) plasma levels (LPA Test, Rolf Greiner Biochimica, Flacht, Germany) was performed at the day of coronary angiography. Details for the other cohorts are described in the appendix pages 4-5.

### **Statistical analysis**

Continuous data are presented as mean  $\pm$  SD when normally distributed or as median and interquartile ranges for variables with skewed distribution. Categorical data are presented as percentages. Statistical differences between continuous variables were determined using one-way ANOVA, Kruskal–Wallis test, or chi-squared test for categorical variables.

In LURIC, the association between Lp(a) plasma levels divided in tertiles as well as LPA SNP carrier status and all-cause as well as cardiovascular mortality was studied using Cox regression analyses with/without adjustment for age, sex, diabetes mellitus, systolic blood pressure, body mass index, smoking status, estimated glomerular filtration rate and LDL-cholesterol.

In sensitivity analyses we determined the association between Lp(a) plasma levels and mortality in LURIC in patients with/without statin treatment or divided into two groups using a cut-off at LDL-C of 130 mg/dL. Moreover, to examine the proportion of variance of Lp(a) caused by the LPA SNPs rs10455872 and rs3798220,  $\eta^2$  was calculated.

Positive LPA SNP carrier status was defined as heterozygosity or homozygosity for the minor alleles of rs10455872 and/or rs3798220. In HCS, KAROLA, WENBIT/WECAC, PROSPER and ATHEROGENE, similar analyses were performed to examine the association between tertiles of Lp(a) and the composite cardiovascular end-points. Results of crude models as well as models adjusted for the following well-established cardiovascular risk factors, i.e. age, sex, diabetes mellitus, systolic blood pressure, body mass index, smoking status, estimated glomerular filtration rate, and LDL-cholesterol are reported. Hazard ratios (HRs) with 95% confidence intervals (CIs) are reported.

To determine the association between tertiles of Lp(a) as well as LPA SNP carrier status and Friesinger score, generalized linear models were used to estimate the marginal (adjusted) means of Friesinger score. Adjustments were made for age, sex, diabetes mellitus, systolic blood pressure, body mass index, smoking status, estimated glomerular filtration rate and LDL-cholesterol.

To analyze the association of the Lp(a) SNPs with cardiovascular outcome in the GENIUS-CHD consortium, meta-analyses using log hazard ratios and their standard errors derived from unadjusted Cox regression models of the association of rs10455872 and rs3798220 with fatal cardiovascular events and all-cause mortality from every cohort included were performed. Standard normal random effects meta-analysis was performed using the R-package 'metaplust' (v 0.7-8).

**Role of the funding source**

No role of the funding source. The corresponding author had full access to all data and the final responsibility to submit for publication.

## Results

3,313 participants of LURIC with Lp(a) measurements and genotyping were included in the present analyses. Baseline characteristics of these participants are shown in **Table 1**. Besides LDL-C and gender distribution, the prevalence of traditional cardiovascular risk factors such as age, reduced estimated glomerular filtration rate (eGFR), diabetes mellitus, smoking, or hypertension was not significantly different across tertiles of Lp(a) (tertile 1  $\leq$  10.0 mg/dL, tertile 2 10.1-26.0 mg/dL, tertile 3  $>$  26.0 mg/dL). The prevalence of CHD at baseline was 77.9 %. Following the strategy of a recent meta-analysis<sup>4</sup>, we divided Lp(a) in tertiles, thereby also minimizing the influence of different methodology used to measure Lp(a). In patients within the highest study-specific tertile of Lp(a), the prevalence of angiographically defined CHD was greater (81.9 % vs. 75.7 %) as compared to those in the lower tertile of Lp(a).

### **LPA genetic variants and Lp(a) levels**

In LURIC, *LPA* SNP rs10455872 data were available in 3058 participants and *LPA* SNP rs3798220 data in 3286 participants. 524 participants (15.9 %) carried any *LPA* minor allele; ten participants carried a minor allele in *LPA* SNP rs10455872 and rs3798220. As previously reported<sup>14</sup>, in participants with Lp(a) plasma levels within the highest tertile, the frequencies of the minor alleles of rs10455872 and of rs3798220 were greater ( $P < 0.001$  each, **Table 1**). Notably, the number of copies of the minor allele for each *LPA* SNP was strongly associated with higher median Lp(a) plasma levels ( $P < 0.001$ ) in an almost linear fashion (**appendix page 23**). For each minor allele of the *LPA* SNPs carried, median Lp(a) was higher by 250 %.

### **Association with angiographic CHD**

We next determined the association of Lp(a) plasma levels and *LPA* SNPs with angiographically documented CHD (**Figure 1A and appendix pages 6-7**). Compared to patients with low Lp(a) (i.e. tertile 1), patients with Lp(a) within tertile 3 had a significantly higher risk for angiographic CHD (HR 1.44, 95% CI 1.14 to 1.83). Similar results were obtained for carriers of *LPA* risk variants, in whom odds for angiographic CHD was also significantly higher (OR 1.88, 95% CI 1.40 to 2.53), suggesting that Lp(a) causally impacts the development of CHD.

We further examined the association between Lp(a) levels and *LPA* SNP carrier status with the Friesinger score as a measure for the severity of angiographic CHD (**Figure 1B**). Both, elevated Lp(a) plasma levels and *LPA* minor alleles were associated with higher Friesinger

scores ( $P < 0.001$  for tertile 3 of Lp(a) concentration and  $P < 0.001$  for *LPA* SNP carriers), indicating more severe CHD, which is in line with previous studies<sup>21,22</sup>.

### **Association of Lp(a) levels with outcomes**

Next, we analyzed the association of elevated Lp(a) levels with subsequent all-cause and cardiovascular mortality. During a median follow-up of 9.9 years, 995 participants (30.0 %) of the LURIC study died, 622 due to CVD (18.8 % of all participants). Tertiles of Lp(a) were neither associated with all-cause nor cardiovascular mortality (**Figure 2A and appendix, page 8**). Adjustment for potential confounders did not change this observation. In additional analyses, this association was not modified (i.e. interact with) either LDL-C or statin treatment (**appendix page 9**).

To validate these findings, we analyzed the association between Lp(a) plasma levels and subsequent cardiovascular mortality in five additional and independent cohorts (HCS, KAROLA, WENBIT/WEAC, PROSPER, ATHEROGENE) with 10,195 participants with prevalent CHD. Baseline characteristics of these studies are shown in **appendix pages 10-14**. Notably, in all five contemporary cohorts of patients with stable CHD, tertiles of Lp(a) did not show any association with the composite cardiovascular end-point (events HCS: 218 (42.4%), KAROLA: 263 (25.2%)) or cardiovascular mortality (events WENBIT/WEAC: 416 (10.0%), PROSPER: 130 (7.0%), ATHEROGENE 230 (8.8%)) during follow-up (**Figure 2B and appendix pages 15-19**).

### **Association of *LPA* genetic variants with outcomes**

We next examined the association between *LPA* SNPs and mortality in LURIC. Notably, we did not observe a significant association between either *LPA* SNP and all-cause or cardiovascular mortality during follow-up (**Figure 2A and appendix page 20**).

To validate these findings still further we performed a meta-analysis of log hazard ratios and their standard errors in 24 studies from the recently formed GENIUS-CHD consortium comprising 106,353 participants with established CHD. Here we examined the association of both *LPA* risk variants and all-cause as well as cardiovascular mortality during follow-up. Baseline characteristics of the contributing studies of GENIUS-CHD are shown in **appendix pages 21-22**. Notably, both minor alleles of *LPA* (*rs10455872* and of *rs3798220*) were not associated with increased all-cause mortality (**Figure 3A+B**) or cardiovascular mortality (**Figure 3C+D**).

## Discussion

In this study of patients with confirmed or suspected CHD, the concentration of Lp(a) at the time of recruitment and the number of minor alleles at two bi-allelic SNPs at the *LPA* locus were positively related to the presence and burden of CHD<sup>14,21,22</sup>. In contrast, we found that neither Lp(a) plasma concentrations nor *LPA* SNPs showed any association with cardiovascular or all-cause mortality during long-term follow-up in patients with established CHD, a finding we validated in 29 studies comprising 116,548 participants.

For many years, Lp(a) has been known to be associated with risk for CHD, independent of traditional cardiovascular risk factors<sup>4-6,23-25</sup>. These findings mainly derive from studies on apparently healthy persons in the general population<sup>4-6,25</sup> rather than from investigations of patients with established CHD. Genetic diversity at the *LPA* locus including *rs10455872* and *rs3798220* has been associated with the Lp(a) concentration in the plasma and with incident cardiovascular disease<sup>6,14</sup>. A recent study has shown that *LPA* KIV2 repeats as well as Lp(a) serum levels were associated with CHD prevalence<sup>26</sup>. A causal link between Lp(a) and atherosclerosis development is therefore likely and the current findings are completely in line with those reported previously.

However, in the LURIC study and in the five independent validation cohorts of patients with established CHD and in 24 studies from the GENIUS-CHD consortium, we did not find any clear association of Lp(a) concentrations or *LPA* variants and subsequent long-term mortality. These findings at least raise the possibility that the association of Lp(a) with risk in patients with CHD is weaker than in healthy persons, which may be due to competing risks commonly prevalent in this patient population. In one of the earlier meta-analyses<sup>4</sup>, the risk ratio for CHD in general population based studies was 1.7 (95% CI 1.4 to 1.9) when the top tertile was compared with the lowest tertile of Lp(a), but only 1.3 (95 % CI 1.1 to 1.6) in nine studies of patients with pre-existing comorbidities (two studies in dialysis patients, one in diabetes mellitus, six in CHD). The latter was mainly driven by the contribution of the Scandinavian Simvastatin Survival Study (4S), which had recruited patients with severe hypercholesterolemia not representative of all CHD and accounted for three fourth of this evidence. Notably in 4S, total cholesterol was between 212 and 309 mg/dL, which is considerably higher than in LURIC or the studies of GENIUS-CHD, limiting generalization of the findings to cohorts with lower total cholesterol. Only one of the eight remaining studies reported a significant association between Lp(a) and incident CHD<sup>4</sup>. Another, more recent publication examining Lp(a) in established CHD has also indicated a modest, non-significant

relationship between Lp(a) and future events in studies with mean LDL-C below 130 mg/dL at baseline, and a stronger association in patients with LDL-C greater than 130 mg/dL<sup>17</sup>.

Taken together, the association between Lp(a) and cardiovascular events may therefore be modified by LDL-C, and, beyond this, also by the high levels of statin use. While we were not able to detect such interactions in the present analyses, it is worth noting that baseline LDL-C in LURIC was  $117\pm 34$  mg/dL and on average  $130\pm 38$  mg/dL in the studies of the GENIUS-CHD consortium and as such we were unable to examine the association of Lp(a) with outcomes at very high levels of LDL-C. Adjustments for other potential confounders investigated at baseline also did not modify our findings, although we were unable to account for other factors that may have changed during follow-up such as LDL-C. However, considering the poor adherence with statins in Germany, we suspect the impact of time dependent changes of LDL-C is unlikely, at least in German cohorts contributing to our analysis<sup>27</sup>.

There are other limitations that need consideration. Firstly, Lp(a) plasma levels in LURIC and in the validation cohorts have been measured using different methods. To exclude biases caused by different calibrations of these assays, all risk estimates were calculated for tertiles of Lp(a) calculated within each cohort. Nevertheless, we cannot entirely exclude the possibility that Lp(a) plasma levels were altered by the initial cardiovascular event itself or by changes during follow-up. Secondly, the current study has focused only on all-cause and cardiovascular mortality, while others have combined a range of fatal and non-fatal cardiovascular events<sup>4-6,17</sup>. We have preferred this strategy because it is arguably robust against differences between studies and changes over time in the definition and adjudication of non-fatal events<sup>28</sup>. This could have reduced our statistical power due to fewer events and meant we missed potentially very small effect sizes. The possibility of a type 2 error remains although with the sample size afforded by our multiple replication cohorts we anticipate this risk is minimal. Although we did not find evidence for an effect of Lp(a) above 50 mg/dL (not shown) beyond which the recent ESC and EAS guideline considers risk significant<sup>29</sup>, we cannot rule out that extreme concentrations would still have an impact. Finally, we cannot currently exclude the impact of Lp(a) levels or genetic variants on risk of subsequent non-fatal events in contrast to fatal events given that such differences have been described for other risk factors<sup>30</sup>. Ischemic and/or thrombotic events, fatal and non-fatal, might be more specifically related to Lp(a) than the totality of CVD deaths. These will require further study as outcome data emerges, particularly since Lp(a) levels appeared to associate similarly with fatal CHD and non-fatal MI in prior analyses in patients without CHD<sup>6</sup>.

To the best of our knowledge, this is the largest study in which the association of Lp(a) levels and SNPs at the *LPA* locus with outcomes in patients with established CHD has been examined simultaneously. Our results, and others show that Lp(a) levels and *LPA* SNPs promote early development of atherosclerosis and associate with greater angiographic severity of CHD. Further, it has been shown that patients with established CHD who carry Lp(a) increasing SNPs are more likely to have earlier CHD onset and have greater susceptibility to atherosclerotic manifestations outside of the coronary tree<sup>21</sup>, supporting a role of Lp(a) in atherosclerosis progression. The lack of association of Lp(a) with CVD fatality in established CHD is thus a surprising finding that we do not have a final explanation for. Among the possible explanations would be index event or survival biases. These cannot be fully excluded, but are unlikely to have impacted our findings significantly as the minor allele frequencies of the *LPA* SNPs were identical to those reported in the control populations including the PROCARDIS cohort and other cohorts<sup>14</sup> and given the lack of imbalances of patients characteristics across genotypes. It is important to note that although Lp(a) concentrations would not be useful for predicting mortality, CHD patients with high Lp(a) could still benefit from Lp(a) lowering, as it might attenuate disease progression.

Screening for elevated Lp(a) has been recommended in persons at intermediate or high risk of CVD or CHD according to conventional criteria<sup>3</sup>. Given the broad evidence in favor of Lp(a) as a marker of risk in clinically healthy persons<sup>3,24</sup>, our data would indicate that it might be more rewarding to integrate Lp(a) into risk stratification in primary rather than in secondary prevention. We acknowledge, however, that markedly increased Lp(a) plasma concentrations in patients with established CHD may be helpful to trigger an intensive screening of family members to improve early preventive measures for the carriers.

Importantly, interventions to lower Lp(a) are scarce. While drug therapies may eventually be used for lowering Lp(a), it has to be determined to which extent Lp(a) lowering by PCSK9 inhibiting antibodies affects cardiovascular outcomes besides their strong effect on lowering of LDL-C<sup>16</sup>. More specific therapies targeting Lp(a) directly such as anti-sense oligonucleotides are in development and testing stages and will shed further light on the value of reducing Lp(a) in the future<sup>31</sup>.

In conclusion, we found that while plasma Lp(a) levels and genetic variants that strongly determine Lp(a) levels are associated with CHD burden and severity, however, neither predict risk of future subsequent cardiovascular or total mortality among participants with established CHD. While the discrepancy with findings in general populations where Lp(a) increases risk of a first CHD event requires further investigation, these data suggest that use



of Lp(a) as a risk marker may be more useful in predicting first CHD event onset rather than progression to death after a CHD event.

## Research in context

### Evidence before this study

Plasma Lp(a) is a recognized emerging risk factor for coronary heart disease (CHD). We performed a systematic search in MEDLINE using the terms 'lipoprotein(a)' or 'lp(a)' to identify studies reporting on the association between Lp(a) and cardiovascular risk. Last search has been performed on May 15, 2016. Several studies show a clear association between elevated Lp(a) plasma levels and an increased risk for atherosclerotic CVD in general populations. However, such an association is weak or absent in fewer and underpowered studies of patients with established CHD. Given that Lp(a) plasma levels are genetically determined by two SNPs in *LPA* loci (*rs10455872* and *rs3798220*), larger epidemiologic and genetic association studies are now feasible to explore the role of Lp(a) in patients with CHD. Importantly, therapies for reducing Lp(a) are also emerging. Thus, a greater understanding of the role of Lp(a) in patients with established CHD would aid its use as a risk stratification biomarker and treatment target in this population.

### Added value of this study

Our study examined the association between Lp(a) concentrations and two common variants at the *LPA* locus with (1) the prevalence and severity of CHD and (2) mortality during long-term follow-up in patients with established CHD. In 29 independent cohorts consisting of 116,548 participants during long-term follow-up, neither Lp(a) concentrations nor *LPA* genetic variants were associated with cardiovascular or all-cause mortality during follow-up.

### Implications of all the available evidence

While the observational data for measuring Lp(a) for risk stratification in general populations is robust, our findings raise questions about the value of doing this in patients with established CHD. The reasons for the discrepancy require further detailed study. Importantly, therapies to reduce Lp(a) are emerging such as PCSK9 inhibitors and antisense agents.

## References

1. Writing Group M, Mozaffarian D, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. *Circulation* 2016; **133**(4): e38-60.
2. Lamina C, Kronenberg F. The mysterious lipoprotein(a) is still good for a surprise. *The lancet Diabetes & endocrinology* 2013; **1**(3): 170-2.
3. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J* 2010; **31**(23): 2844-53.
4. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. *Circulation* 2000; **102**(10): 1082-5.
5. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. *Circulation* 2008; **117**(2): 176-84.
6. Emerging Risk Factors C, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. *JAMA* 2009; **302**(4): 412-23.
7. Utermann G. The mysteries of lipoprotein(a). *Science* 1989; **246**(4932): 904-10.
8. Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. *The lancet Diabetes & endocrinology* 2013; **1**(3): 220-7.
9. Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, Function, and Genetics of Lipoprotein(a). *J Lipid Res* 2016.
10. White AL, Rainwater DL, Hixson JE, Estlack LE, Lanford RE. Intracellular processing of apo(a) in primary baboon hepatocytes. *Chemistry and physics of lipids* 1994; **67-68**: 123-33.
11. Hoover-Plow J, Huang M. Lipoprotein(a) metabolism: potential sites for therapeutic targets. *Metabolism: clinical and experimental* 2013; **62**(4): 479-91.
12. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. *J Clin Invest* 1992; **90**(1): 52-60.
13. Schmidt K, Kraft HG, Parson W, Utermann G. Genetics of the Lp(a)/apo(a) system in an autochthonous Black African population from the Gabon. *European journal of human genetics : EJHG* 2006; **14**(2): 190-201.
14. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. *N Engl J Med* 2009; **361**(26): 2518-28.

15. Li J, Lange LA, Sabourin J, et al. Genome- and exome-wide association study of serum lipoprotein (a) in the Jackson Heart Study. *Journal of human genetics* 2015; **60**(12): 755-61.
16. Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. *J Am Coll Cardiol* 2014; **63**(13): 1278-88.
17. O'Donoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. *J Am Coll Cardiol* 2014; **63**(6): 520-7.
18. Forbes CA, Quek RG, Deshpande S, et al. The relationship between Lp(a) and CVD outcomes: a systematic review. *Lipids Health Dis* 2016; **15**: 95.
19. Winkelmann BR, März W, Boehm BO, et al. Rationale and design of the LURIC study-- a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. *Pharmacogenomics* 2001; **2**(1 Suppl 1): S1-73.
20. Patel RS, Asselbergs FW. The GENIUS-CHD consortium. *Eur Heart J* 2015; **36**(40): 2674-6.
21. Helgadottir A, Gretarsdottir S, Thorleifsson G, et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. *J Am Coll Cardiol* 2012; **60**(8): 722-9.
22. Bjornsson E, Gudbjartsson DF, Helgadottir A, et al. Common sequence variants associated with coronary artery disease correlate with the extent of coronary atherosclerosis. *Arterioscler Thromb Vasc Biol* 2015; **35**(6): 1526-31.
23. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Qunici GB. Lipoprotein Lp(a) and the risk for myocardial infarction. *Atherosclerosis* 1981; **38**(1-2): 51-61.
24. Emerging Risk Factors C, Di Angelantonio E, Gao P, et al. Lipid-related markers and cardiovascular disease prediction. *JAMA* 2012; **307**(23): 2499-506.
25. Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). *Circulation* 2014; **129**(6): 635-42.
26. Saleheen Danesh. Apolipoprotein(a) isoform size, lipoprotein(a) concentration and coronary artery disease: A Mendelian randomisation analysis.
27. Gitt AK, Lautsch D, Ferrieres J, et al. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. *Atherosclerosis* 2016; **255**: 200-9.
28. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of

the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). *Eur Heart J* 2007; **28**(19): 2375-414.

29. Authors/Task Force M, Catapano AL, Graham I, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Atherosclerosis* 2016; **253**: 281-344.
30. Chan K, Patel RS, Newcombe P, et al. Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. *J Am Coll Cardiol* 2013; **61**(9): 957-70.
31. Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. *Lancet* 2015; **386**(10002): 1472-83.

## Acknowledgements

Folkert W. Asselbergs is supported by a Dekker scholarship-Junior Staff Member 2014T001 – Netherlands Heart Foundation and UCL Hospitals NIHR Biomedical Research Centre. Riyaz S Patel is supported by a BHF clinical intermediate fellowship. GeneBank was supported in part by NIH grants P01HL098055, P01HL076491, and R01HL103931. SLH is also partially supported by a gift from the Leonard Krieger Fund. INVEST was supported by the University of Florida and grants from BASF Pharma and Abbott Laboratories. INVEST genetic substudy was supported by the National Institute of Health Pharmacogenetics Research Network grant U01-GM074492, NIH R01 HL074730, UF Opportunity Fund, and Abbott Laboratories. The genome-wide genotyping and imputation in INVEST were performed by the RIKEN Center for Integrative Medical Sciences. The Krakow cohort was supported by the grant from the Polish Ministry of Science and Higher Education, no. NN402083939 and the National Science Centre, no. 2013/09/B/NZ5/00770. LIFE-Heart is supported by LIFE – Leipzig Research Center for Civilization Diseases, Universität Leipzig. LIFE is funded by means of the European Union, by the European Regional Development Fund (ERDF) and by means of the Free State of Saxony within the framework of the excellence initiative. We are grateful to the patients, their families, and the physicians involved in the TexGen study. Dr. Cresci's effort is supported, in part, by the National Institutes of Health (Cresci R01 NR013396). TRIUMPH was sponsored by the National Institutes of Health: Washington University School of Medicine SCCOR Grant P50 HL077113. VHS was supported by the Cariverona Foundation, Verona, Italy. Dr. Thanassoulis is supported by a Fonds de la Recherche en Santé du Québec (FRQS) Chercheur Boursier Clinicien Salary Award. This work was supported by CIHR grant CIHR MOP-119380 and HSFC G-15-0009339 to Dr. Thanassoulis as well as, in part, by CIHR IGO- 86113 to Dr. Pilote. The RISCA cohort was supported in part by the FRSQ, the Heart and Stroke Foundation of Canada, and unrestricted grants from Merck Frosst Canada and Pfizer Canada. The PRAXY cohort was supported by the Canadian Institutes of Health Research and the Heart and Stroke Foundations of Quebec, Nova Scotia, Alberta, Ontario, Yukon, and British Columbia (MOP-89369). The AtheroGene study is supported by a grant of the 'Stiftung Rheinland-Pfalz für Innovation', Ministry of Science and Education (AZ 15202–386261/545), Mainz, by the MAIFOR grant 2001 of the Johannes Gutenberg-University Mainz, Germany, and by grants from the Fondation de France (no. 2002004994), the French Ministry of Research (ACI IMPBIO 032619) and the Institut National de la Santé et de la Recherche Médicale (Programme National de Recherches sur les Maladies Cardiovasculaires A04052DS). The KAROLA study was supported by the German Federal Ministry of Education and Research (01GD9820/0, 01ER0814), by the Willy Robert Pitzer

Foundation, Bad Nauheim, Germany, and by the Waldburg-Zeil Clinics Isny, Germany. The AtheroGene study is part of the European collaborative research project BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) which is supported by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. HEALTH-F2-2011-278913 (BiomarCaRE). Nilesh Samani is supported by the British Heart Foundation and is also a NIHR Senior Investigator. Riyaz S Patel is supported by a BHF Fellowship, FS/14/76/30933. WENBIT/BECAC has been funded by the Advanced Research Program and Research Council of Norway; the Department of Heart Disease at Haukeland University Hospital; the Norwegian Foundation for Health and Rehabilitation; the Norwegian Heart and Lung Patient Organization; the Norwegian Ministry of Health and Care Services; the Western Norway Regional Health Authority. GeneBank was supported in part by NIH grants P01HL098055, P01HL076491, and R01HL103931. SLH is also partially supported by a gift from the Leonard Krieger Fund. The authors thank deCODE collaborators for discussion and sharing data from the deCODE study. The authors thank the CURE investigators. Stephen Zewinger is supported by Deutsche Nierenstiftung and Else-Kroener Fresenius Stiftung. Thimoteus Speer is supported by Else-Kroener Fresenius Stiftung and Deutsche Forschungsgemeinschaft (DFG).

## **Declaration of interest**

Dr. Koenig reports personal fees from AstraZeneca, personal fees from Novartis, personal fees from Pfizer, personal fees from The Medicines Company, personal fees from GSK, personal fees from DalCor, grants and non-financial support from Abbott, Roche Diagnostics, Beckmann, Singulex, personal fees from Sanofi, personal fees from Berlin-Chemie, personal fees from Kowa, personal fees from Amgen, outside the submitted work. Dr. Rothenbacher reports grants from German Federal Ministry of Research and Education, grants from Pitzer Foundation in Bad Nauheim/Germany, during the conduct of the study; personal fees from Novartis Pharma, personal fees from MEDA Pharma, outside the submitted work. Dr. Brenner reports that the KAROLA study was supported in parts by grants of the German Federal Ministry of Education and Research (01GD9820/0, 01ER0814), the Willy Robert Pitzer Foundation, Bad Nauheim, Germany, and by the Waldburg-Zeil Clinics in Isny. Dr. Sattar reports grants, personal fees and other from Amgen, outside the submitted work. Dr. Cooper-DeHoff reports grants from NIH, outside the submitted work. Dr. Scholz reports grants and personal fees from Merck Serono, outside the submitted work. Dr. Cresci reports grants from National Institutes of Health (Cresci R01 NR013396), during the conduct of the study. Dr. Tang reports grants from National Institutes of Health, during the conduct of the study; grants from National Institutes of Health, outside the submitted work. Dr. Eriksson reports grants from AstraZeneca, grants from GlaxoSmithKline, during the conduct of the study. Dr.

Held reports grants from GlaxoSmith Kline, grants from BristolMyerSquibb, grants and personal fees from AstraZeneca, outside the submitted work. Dr. Hagström reports grants from GSK , during the conduct of the study. Dr. Wallentin reports institutional grants from GlaxoSmithKline, AstraZeneca, during the conduct of the study; institutional grants from Merck & Co, Abbott, Roche, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, outside the submitted work. Dr. Åkerblom reports grants from Roche Diagnostics, grants from AstraZeneca, during the conduct of the study. Dr. Thanassoulis reports grants from Canadian Institutes of Health Research, grants from Heart and Stroke Foundation of Canada, during the conduct of the study; personal fees from Ionis Pharmaceuticals, grants from Ionis Pharmaceuticals, personal fees from Amgen, personal fees from Servier Canada, outside the submitted work. Dr. Asselbergs reports grants from Dutch Heart Foundation, during the conduct of the study. Dr. Krämer reports personal fees from Chiesi, personal fees from BMS, grants and personal fees from Astellas, personal fees from Pfizer, personal fees from Bayer, grants from Opsona, outside the submitted work. Dr. Hingorani reports grants from British Heart Foundation during the conduct of the study. Dr. März reports grants and personal fees from Siemens Diagnostics, grants and personal fees from Aegerion Pharmaceuticals, grants and personal fees from AMGEN, grants and personal fees from Astrazeneca, grants and personal fees from Danone Research, grants and personal fees from Sanofi/Genzyme, personal fees from Hoffmann LaRoche, personal fees from MSD, grants and personal fees from Pfizer, personal fees from Sanofi, personal fees from Synageva, grants and personal fees from BASF, grants from Abbott Diagnostics, grants and personal fees from Numares AG, other from Synlab Holding Deutschland GmbH, outside the submitted work. The other authors reported no conflict of interest.



## Figure legends

**Figure 1:** (A) Association between tertiles of Lp(a) or carrier status of *LPA* SNPs, respectively, and coronary heart disease as determined by logistic regression analyses. Multivariate analyses were adjusted for age, sex, diabetes, systolic blood pressure, body mass index, smoking status, estimated glomerular filtration rate, LDL-C, and lipid-lowering therapy. (B) Marginal means (95 % CI) of the severity of coronary disease (Friesinger score) according to tertiles of Lp(a) or *LPA* SNP carrier status. Analyses were adjusted for age, sex, diabetes, systolic blood pressure, body mass index, smoking status, estimated glomerular filtration rate, LDL-C, and lipid-lowering therapy.

**Figure 2:** (A) Association between tertiles of Lp(a) as well as *LPA* SNP carrier status and all-cause as well as cardiovascular mortality in participants of the LURIC study as determined by Cox regression analyses adjusted for age, sex, diabetes, systolic blood pressure, body mass index, smoking status, estimated glomerular filtration rate, LDL-C, and lipid-lowering therapy. (B) Association between tertiles of Lp(a) and composite cardiovascular end-point (HCS and KAROLA) and cardiovascular mortality (WENBIT/WECAC, PROSPER and ATHEROGENE) as determined by Cox regression analyses. Multivariate analyses were adjusted for age, sex, diabetes, systolic blood pressure, body mass index, smoking status, estimated glomerular filtration rate, and LDL-C.

**Figure 3:** Forest plot of risk ratios for all-cause (A) and (B) as well as cardiovascular mortality (C) and (D) according to *LPA* SNPs rs3798220 (A) and (C) as well as rs10455872 (B) and (D) in studies of GENIUS-CHD consortium. Markers represent point estimates of risk ratios; marker size represents study weight in random-effect meta-analysis. Horizontal bars indicate 95% confidence intervals.

**Table 1**

Baseline characteristics of the LURIC cohort, overall and stratified according to tertiles of Lp(a)

	<b>Overall (n=3313)</b>	<b>Lp(a) Tertile 1 ≤ 10.0 mg/dL (n=1146)</b>	<b>Lp(a) Tertile 2 10.1-26.0 mg/dL (n=1065)</b>	<b>Lp(a) Tertile 3 &gt;26.0 mg/dL (n=1102)</b>	<b>P*</b>
<b>Age</b>	62.7±10.6	62.8±10.7	62.8±10.7	62.4±10.4	0.445
<b>Sex</b>					
<b>Male</b>	2308 (69.7%)	842 (73.5%)	735 (69.0%)	731 (66.3%)	0.001
<b>Female</b>	1005 (30.3%)	304 (26.5%)	330 (31.0%)	371 (33.7%)	0.001
<b>BMI (kg/m<sup>2</sup>)</b>	27.5±4.1	27.5±4.1	27.7±4.2	27.2±3.9	0.066
<b>Systolic blood pressure (mmHg)</b>	141±24	142±23	140±24	141±24	0.184
<b>Lp(a) (mg/dL)</b>	16.0 (31.0)	5.0 (6.4)	16.0 (7.1)	58.0 (44.7)	<0.001
<b>Any LPA SNP minor allele<sup>&amp;</sup></b>	524 (15.9%)	73 (6.4%)	81 (7.7%)	370 (34.0%)	<0.001
<b>LPA SNP rs10455872<sup>§</sup> A/G</b>	399 (13.1%)	56 (5.2%)	63 (6.4%)	280 (27.8%)	<0.001
<b>LPA SNP rs10455872<sup>§</sup> G/G</b>	10 (0.3%)	0	1 (0.1%)	9 (0.9%)	<0.001
<b>LPA SNP rs3798220<sup>§</sup> T/C</b>	124 (3.8%)	17 (1.5%)	19 (1.8%)	88 (8.1%)	<0.001
<b>LPA SNP rs3798220<sup>§</sup> C/C</b>	1 (<0.1%)	0	0	1 (0.1%)	<0.001
<b>Total cholesterol (mg/dL)</b>	192±39	189±39	191±38	197±40	<0.001
<b>Triglycerides (mg/dL)</b>	173±118	179±136	173±115	167±99	0.089
<b>HDL-C (mg/dL)</b>	39±11	38±11	39±11	39±10	0.037
<b>LDL-C (mg/dL)</b>	117±34	112±34	116±33	122±36	<0.001
<b>VLDL-C (mg/dL)</b>	37±26	39±30	36±26	36±24	0.002
<b>Apolipoprotein B (mg/dL)</b>	104±25	103±24	103±24	107±25	<0.001
<b>Glycated hemoglobin (%)</b>	6.3±1.2	6.3±1.4	6.3±1.2	6.3±1.2	0.203
<b>eGFR CKD-EPI (ml/min/1.73m<sup>2</sup>)</b>	81.7±20.1	82.1±20.7	81.5±20.1	81.4±19.6	0.602
<b>hsCRP (mg/L)</b>	3.4 (7.3)	3.6 (8.4)	3.4 (7.1)	3.2 (6.3)	0.037
<b>IL-6 (ng/L)</b>	3.2 (4.3)	3.3 (4.8)	3.2 (4.2)	3.2 (4.1)	0.235
<b>Fibrinogen (mg/dL)</b>	377 (132)	370 (142)	380 (128)	381 (124)	0.619
<b>Friesinger Score</b>	5.4±3.9	5.1±3.9	5.2±4.0	5.9±3.8	<0.001
<b>Coronary artery disease</b>	2580 (77.9%)	867 (75.7%)	810 (76.1%)	903 (81.9%)	<0.001
<b>Previous myocardial infarction</b>	1365 (41.2%)	446 (38.9%)	448 (42.1%)	471 (42.7%)	0.144
<b>Diabetes mellitus</b>	1322 (39.9%)	467 (40.8%)	440 (41.3%)	415 (37.7%)	0.170

<b>Lipid lowering therapy</b>	1607 (48.5%)	489 (42.7%)	529 (49.7%)	589 (53.4%)	<0.001
<b>Smoking</b>	2120 (64.0%)	741 (64.7%)	681 (63.9%)	698 (63.3%)	0.808
<b>Hypertension</b>	2409 (72.7%)	826 (72.1%)	762 (71.5%)	821 (74.5%)	0.255
<b>Total deaths (all-cause)</b>	994 (30.0%)	361 (31.5%)	322 (30.2%)	311 (28.2%)	0.233
<b>Cardiovascular deaths</b>	621 (18.9%)	232 (20.4%)	186 (17.6%)	203 (18.5%)	0.129

Values are presented as mean (SD), median (IQR) or number (%). BMI=body mass index. HDL=high-density lipoprotein. LDL=low-density lipoprotein. VLDL=very low-density lipoprotein. Lp(a)=lipoprotein(a). IL-6=interleukin-6. eGFR=estimated glomerular filtration rate. hsCRP=high sensitivity C-reactive protein.

- 5 \* Comparison between tertiles of Lp(a).  $p < 0.05$  was considered significant. § *LPA* SNP rs10455872 data were available in 3058 participants. § *LPA* SNP rs3798220 data were available in 3286 participants. & Ten participants carried a minor allele in *LPA* SNP rs10455872 and rs3798220. Any *LPA* SNP minor allele information is available in 3287 participants. In 23 participants, no information on *LPA* SNPs is available.

## Contributors

F.B., S.B., R.M.C.D., J.A.J., I.K., U.L., W.M., M.N., R.N.D., A.M.R., D.R., H.S., R.B.S., A.H., T.S., L.W., S.Z. study design. A.A., H.A., F.W.A., C.M.B., F.B., S.B., E.B., P.B., P.S.B., L.P.B., H.B., G.B., S.C., K.D., H.D., J.C.E., R.M.C.D., J.A.J., E.H., J.H., S.L.H., C.H., I.H.,

5 J.W.J., I.K., M.K., G.D., Y.A.K., W.K., R.L., C.L., K.J.L., U.L., V.V.L., A.L., A.M., W.M., B.D.H., R.M., U.M., C.P.N., O.N., N.M., D.G., O.O., G.P., A.P.P., V.A.C., R.N.D., A.M.R., A.A.Q., D.R., A.L., A.M., C.H.S., N.S., N.Sa., H.S., T.St., A.F.S., R.B.S., M.S., J.S., C.S., J.G.S., T.S., J.Sp., A.S., G.F.T.S., W.S., M.Ka., M.Sa., W.H.W.T., G.S.T., J.T., S.T., R.J., S.S.V., C.W., L.W., S.Z., L.P., A.H. data collection. H.A., F.W.A., F.B., E.B., P.B., P.S.B.,

10 H.B., G.B., S.C., K.D., H.D., J.C.E., N.E., A.F., D.F., Y.G., H.G., J.H., S.L.H., C.H., M.K., G.D., M.K., Y.A.K., D.K., R.L., C.L., V.V.L., A.L., A.M., P.L., R.O.M., B.D.H., U.M., C.P.N., O.N., N.M., D.G., O.O., E.R.P., I.P., V.A.C., A.A.Q., D.R., A.L., A.M., C.H.S., N.S., N.Sa., H.S., T.St., A.F.S., M.S., J.S., C.S., J.G.S., T.S., W.S., M.Ka., M.Sa., G.S.T., G.T., J.T., S.T., R.J., S.Tr., R.A.J.S., R.V., S.S.V., E.V., C.W., C.We., S.Z., L.P., A.H. data analysis. H.A.,

15 A.A., F.W.A., E.B., P.B., L.P.B., H.B., G.B., S.C., K.D., J.C.E., D.F., Y.G., R.M.C.D., J.A.J., E.H., J.H., S.L.H., C.H., M.V.H., J.W.J., M.K., G.D., M.K., Y.A.K., W.K., B.K., R.L., C.L., U.L., V.V.L., W.M., R.O.M., B.D.H., U.M., C.P.N., O.N., E.R.P., I.P., V.A.C., A.A.Q., D.R., N.S., N.Sa., H.S., T.St., A.F.S., R.B.S., M.S., C.S., T.S., G.S.T., G.T., J.T., S.T., R.J., S.Tr., R.A.J.S., L.W., S.Z., L.P., A.H. data interpretation. A.A., F.W.A., D.F., Y.G., R.M.C.D., J.A.J.,

20 M.K., G.D., W.K., B.K., U.L., A.H., W.M., R.P., T.S., S.Z. manuscript manuscript writing. A.A., F.W.A., C.M.B., E.B., P.B., L.P.B., H.B., G.B., S.C., K.D., J.C.E., A.F., D.F., H.G., J.H., S.L.H., C.H., M.V.H., J.W.J., M.K., G.D., Y.A.K., C.L., V.V.L., R.O.M., B.D.H., R.M., U.M., C.P.N., M.N., O.N., N.M., D.G., O.O., R.P., E.R.P., I.P., A.P.P., V.A.C., R.N.D., A.M.R., A.A.Q., D.R., N.S., N.Sa., H.S., T.St., A.F.S., M.S., A.S., C.S., T.S., J.Sp., G.F.T.S., W.S.,

25 M.Ka., M.Sa., W.H.W.T., G.S.T., G.T., J.T., S.T., R.J., S.Tr., R.A.J.S., S.S.V., L.W., C.We., S.Z., L.P., A.H. critical revision of the manuscript. R.P. coordinated data collection, analysis for the GENIUS-CHD consortium. V. T. (main analyst of GENIUS-CHD) gathered, processed, pooled and produced outputs with the data obtained from multiple cohorts of GENIUS-CHD.